Overview

KPV is the C-terminal tripeptide lysine-proline-valine, corresponding to residues 11–13 of alpha-melanocyte stimulating hormone (α-MSH). It retains a substantial portion of the anti-inflammatory activity of the parent 13-residue peptide but lacks the pigmentation-driving melanocortin-receptor agonism, because the receptor-binding residues sit N-terminal to the KPV segment.

Most published research on KPV is in animal models of inflammatory bowel disease, dermatological inflammation, and general anti-inflammatory pharmacology.

Mechanism (as reported in the literature)

  • Cytosolic anti-inflammatory activity. Research characterises KPV as entering cells and modulating NF-κB signalling at intracellular sites, distinct from cell-surface melanocortin-receptor activation.
  • Cytokine-panel modulation. Studies indicate reductions in TNF-α, IL-6, and IL-8 expression in intestinal epithelial models and skin inflammation models.
  • Barrier-integrity effects. Animal-model gut studies report preserved tight-junction integrity in colitis models with KPV administration.
  • Antimicrobial activity. Studies describe direct inhibitory effects on select bacterial and fungal strains at higher concentrations.

Research findings

  • Colitis models. Rodent DSS and TNBS colitis models report reduced histological injury scores, cytokine expression, and disease-activity indices with oral or peri-oral KPV administration (Kannengiesser et al., 2008; PMID 18506859).
  • Skin inflammation. Guinea-pig and mouse studies of contact dermatitis and psoriasis-like inflammation report reductions in inflammatory markers with topical KPV.
  • Wound-healing adjunct. Studies report improved healing time in inflamed-wound models.

Common dosing (from reported research protocols)

Community writeups typically describe 200–500 mcg subcutaneous doses daily. Oral preparations described in the inflammatory-bowel research context use larger totals delivered in gastrointestinal-targeted formulations.

Reconstitution

A 5 mg vial reconstituted with 2 mL of bacteriostatic water yields a 2,500 mcg/mL solution.

  • 200 mcg = 0.08 mL = 8 units on a U-100 syringe
  • 500 mcg = 0.20 mL = 20 units

Storage

Reconstituted KPV is refrigerated at 2–8 °C and reported as stable for approximately 30 days.

  • BPC-157 — a distinct healing-recovery peptide with overlapping research context.
  • Thymosin Alpha-1 — a related immune-modulating peptide.
  • Melanotan-II — a full-length melanocortin agonist for mechanistic comparison.

Common stacks

References

  • Kannengiesser, K., et al. (2008). “Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease.” Inflammatory Bowel Diseases, 14(3). PMID 18506859.
  • Dalmasso, G., et al. (2008). “PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.” Gastroenterology, 134(1). PMID 18061180.
  • Brzoska, T., et al. (2008). “α-Melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases.” Endocrine Reviews, 29(5). PMID 18477713.